CN104945333B - 紫苏醇类似物及其制备和应用 - Google Patents
紫苏醇类似物及其制备和应用 Download PDFInfo
- Publication number
- CN104945333B CN104945333B CN201410119248.XA CN201410119248A CN104945333B CN 104945333 B CN104945333 B CN 104945333B CN 201410119248 A CN201410119248 A CN 201410119248A CN 104945333 B CN104945333 B CN 104945333B
- Authority
- CN
- China
- Prior art keywords
- acid
- perilla alcohol
- salt
- alcohol analog
- perilla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000002977 perillyl alcohol derivatives Chemical class 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229940071870 hydroiodic acid Drugs 0.000 claims 1
- 229960000448 lactic acid Drugs 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- 125000002075 perillyl alcohol group Chemical group 0.000 abstract description 2
- 239000012453 solvate Substances 0.000 abstract 1
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 39
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 235000005693 perillyl alcohol Nutrition 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- -1 compound salt Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- NDTYTMIUWGWIMO-SNVBAGLBSA-N (-)-perillyl alcohol Chemical compound CC(=C)[C@H]1CCC(CO)=CC1 NDTYTMIUWGWIMO-SNVBAGLBSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 241000229722 Perilla <angiosperm> Species 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical class CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 150000002627 limonene derivatives Chemical class 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于医药技术领域，涉及一系列紫苏醇类似物及其制备和应用，具有如式Ⅰ结构。本发明还包括紫苏醇类似物药学上可接受的盐和溶剂化物，以及含有所述紫苏醇类似物或其药学上可接受的盐作为活性成分的药物组合物，且可用于治疗癌症。本发明所述的紫苏醇类似物及其药用盐类具有较好的抗癌活性，其制备方法简单可行，易操作。
Description
技术领域：
本发明涉及一系列新的紫苏醇类似物及其制备和应用，还涉及该化合物的盐类和以该化合物或其盐类为活性成分的药物组合物，并用于治疗癌症。本发明还涉及合成系列紫苏醇类似物中间体的制备方法。
背景技术：
紫苏醇（perillyl alcohol）为异戊二烯萜类挥发油，广泛存在于紫苏叶、柑桔、樱桃、薄荷等植物中，可以诱导细胞凋亡、抑制肿瘤细胞增殖、诱导肿瘤细胞再分化，是目前已知的少数几个对肿瘤既有化学预防作用又有化学治疗作用的天然产物（胡东,陈燕.食物来源单萜类物质紫苏醇的抗癌作用[J].临床血液杂志，2001,14(3):141-143）。在肿瘤形成初始阶段，紫苏醇不仅能降低动物模型中肿瘤的发生几率，还能减少肿瘤发生种类，对食道癌（Liston B W,Nines R,Carlton P S,et a1.Perillyl alcohol as a chemopreventiveagent in N-nitro-somethylvenzylamine-induced rat esophageal tumorigenesis[J].Cancer Research,2003,63(10):2399-2403）、结肠直肠癌（Meadows S M,Mulkerin D,Berlin J,et al.Phase II trial of perillyl alcohol with metastatic colorectalcancer[J].International Journal of Gastrointestinal Cancer,2002,32(2-3):125-128）、胰腺癌（Lebedeva I V,Suzz,Vozhilla N,et al.Mechanism of in vitropancreatic cancer cell growth inhibition by melanoma differentiation-associated gene7/interleuk in-24and perillyl alcohol[J].Cancer Research,2008,68(18):7439-7447）和乳腺癌（Yuri T,Danbara N,Tsujita-Kyutoku M,et al.Perillylalcohol inhibits human breast cancer cell growth in vitro and in vivo[J].Breast Cancer Research and Treatment,2004,84(3):251-260,）等肿瘤均有预防和治疗作用，效果显著。在国外已作为抗肿瘤药物进入临床Ⅰ期和临床Ⅱ期研究阶段（Liu G,Oettel K,Ummersen L V,et al.Phase II trial of perilly alcohol(NSC641066)administered daily in patients with metastatic androgen independent prostatecancer[J].Investigational New Drugs,2003,21(3):367-372.Bailey H H,Attia S,Love R R,et al.Phase II trial of daily oral perillyl alcohol(NSC641066)intreatment-refractory metastatic breast cancer[J].Cancer Chemother Pharmacol,2008,62(1):149-157.da Fonseca C O,Schwartsmann G,Fischer J,et al.Preliminaryresults from a phase I/II study of perillyl alcohol intranasal administrationin adults with recurrent maligant gliomas[J].Surgical Neurology,2008,70(3):259-266.）。
国内外对紫苏醇衍生物的化学修饰仅限于三方面：①将紫苏醇的环外羟基以维A酸酯化，合成维A酸类衍生物,目前未见该类衍生物的药理活性报道（Das B C,MahalingamS M,Panda L,et al.Design and synthesis of potential new apoptosis agents:hybrid compounds containing perillyl alcohol and new constrained retinoids[J].Tetrahedron Letters,2010,51(11):1462–1466）。②将紫苏醇环外羟基和葡萄糖成苷键，合成葡萄糖类衍生物，该类衍生物对小鼠肺癌细胞的抑制活性较紫苏醇略高（Xanthakis E,Magkouta S,Loutrari H,et al.Enzymatic synthesis of perillylalcohol derivatives and investigation of their antiproliferative activity[J].Biocatalysis and Biotransformation,2009,27(3):170-178.）。③在羟基α-碳原子上引入磷酸酯结构或将羟基用磷酸酯结构取代。该类化合物对法尼基转移酶和小鼠胚胎成纤维细胞NIH-3T3未见明显抑制作用（Eummer J T,Gibbs B S,Zahn T J.et al.Novellimonene phosphonate and farnesyl diphosphate analogues:design,synthesis,andevaluation as potential protein-farnesyl transferase inhibitors[J].Bioorganic&Medicinal Chemistry,1999,7(2):241-250.）。
紫苏醇水溶性差，口服给药生物利用度低，限制了其临床应用（Liu G,Oettel K,Ummersen L V,,et al.Phase II trial of perilly alcohol(NSC641066)administereddaily in patients with metastatic androgen independent prostate cancer[J].Investigational New Drugs,2003,21(3):367-372.Bailey H H,Attia S,Love R R,etal.Phase II trial of daily oral perillyl alcohol(NSC641066)in treatment-refractory metastatic breast cancer[J].Cancer Chemother Pharmacol,2008,62(1):149-157.）。针对以上问题，借鉴本课题组前期对榄香烯、柠檬烯衍生物抗癌构效关系的研究结果，认为增强化合物的极性和水溶性有利于提高抗肿瘤活性（陈娇娇,董金华,景永奎,等.柠檬烯类似物及其制备方法和用途[P].中国专利,200610081622.7,公开号CN101070300.董金华,徐莉英,景永奎,等.一种β-榄香烯含氮衍生物的制备及应用[P].中国专利,200610080037.5,公开号CN1844105.徐莉英,董金华,景永奎,等.β-榄香烯含氮衍生物及其制备方法和用途[P].中国专利,200610081625.0,公开号CN1850779.）。因此，本发明首次明确提出保持紫苏醇的含双键的单环单萜骨架，在羟基α-碳原子上引入烷基，并在环外烯丙位引入亲水性的含氮基团，从而改善水溶性，提高抗肿瘤活性，合成了本发明所述紫苏醇类似物，并经药理试验研究了其抗肿瘤活性。
发明内容：
本发明以紫苏醇为先导化合物，为提高化合物的极性或亲水性、增强其抗癌活性，在羟基α-碳原子上引入烷基，并在环外烯丙位引入胺类基团，合成了紫苏醇类似物，并经药理试验证明可抑制多种肿瘤细胞增殖，它们的主要作用为抗肿瘤。
本发明提供紫苏醇类似物结构如下式I：
其中，R为C1-C6烷基，优选C1-C4烷基，更优选为甲基、乙基。
NR1R2为带有取代基的哌嗪基，所述取代基选自：C1-C12烷基、C1-C6烷氧基苯基、含有烯键的C1-C6烷基、含有炔键的C1-C6烷基、含有羟基的C1-C6烷基、含有苯基的C1-C6烷基；含氮5-10元杂环；C1-C6烷基、C3-C7环烷基取代的氨基；
优选地，NR1R2为带有取代基的哌嗪基，所述取代基选自：C1-C6烷基、C1-C4烷氧基苯基、含有烯键的C1-C4烷基、含有炔键的C1-C4烷基、含有羟基的C1-C4烷基、含有苯基的C1-C4烷基；含氮5-10元杂环；取代的氨基，所述取代基选自：C1-C4烷基、C3-C6环烷基。
更为优选地，NR1R2为带有取代基的哌嗪基，所述取代基选自：甲基、乙基、丙基、异丙基、甲氧基苯基、乙氧基苯基、苯基甲基、苯基乙基。
优选自如下化合物：
本发明提供紫苏醇类似物及其药用盐类的制备方法，其合成路线如下：
其中，R、NR1R2如权利要求所述。
优选：
本发明上述紫苏醇类似物及其药用盐类的制备过程中所用溶剂为常用的反应溶剂，无特殊要求。
本发明提供了含上述紫苏醇类似物及其药用盐类，指常规的酸加成盐。
所述的药用盐为与与合适的非毒性有机酸或无机酸成的盐。如盐酸，氢溴酸，氢碘酸，硫酸，磷酸，硝酸，乙酸，酒石酸，水杨酸，甲磺酸，丁二酸，柠檬酸，苹果酸，乳酸，富马酸，马来酸等。
本发明提供了一种药物组合物，所述组合物由上述的紫苏醇类似物及其药用盐类和药学上可被接受的赋形剂组成。本发明还提供了紫苏醇类似物及其药用盐类及其组合物在制备抗癌药物中的用途。
本发明所描述的紫苏醇类似物，是为改善紫苏醇的水溶性和提高抗癌活性，而在其分子中引入含氮基团所合成的化合物，这些衍生物可能具有更强的生理活性和较大极性，其氨基便于和酸成盐来达到改善水溶性的目的。
本发明的紫苏醇类似物及其药用盐类具有较好的抗癌活性，其制备方法简单可行，易操作。
具体实施方式：
下面通过实施例来说明本发明的可实施性，本领域的技术人员应当理解，根据现有技术的教导，对相应的技术特征进行修改或替换，仍然属于本发明要求保护的范围。
实施例1的合成通法
在500mL的茄形瓶中加入0.125mol镁丝，100mL干燥的无水乙醚和一小粒碘，滴加卤代烷0.12mol，使反应液保持在微沸状态。加毕后室温搅拌反应1h。稍冷，滴加0.1mol紫苏醛，加毕后室温搅拌1h。冰浴下，加入30mL饱和氯化铵水溶液，将反应液转移至分液漏斗中，分出有机相，水相用乙醚萃取。合并有机相，用饱和盐水溶液洗涤，无水硫酸钠干燥。浓缩后得无色透明液体。
按此合成方法得到：
实施例2的合成通法
将0.08mol实施例1产物，0.26mol醋酸酐溶于25mL吡啶中，室温反应4h。加入2mL甲醇，50mL乙酸乙酯，转移至分液漏斗中，分出有机相，用饱和碳酸氢钠和饱和盐水洗涤，无水硫酸钠干燥。浓缩得无色透明液体，收率94.1%。
按此合成方法得到：
实施例3的合成
在100mL茄形瓶中加入25.8mmol实施例2产物、20mL二氯甲烷和38.7mmol冰醋酸，冰浴下缓慢滴加77.3mmol次氯酸钠水溶液（含有效氯8%）。加毕继续反应30min。加10mLNa2SO3水溶液，分出有机层，水层用二氯甲烷萃取，合并有机相，用水和饱和NaCl溶液洗涤，无水硫酸钠干燥。浓缩得淡黄色液体，收率85.9%。
按此合成方法得到：
实施例4紫苏醇类似物的合成通法
在100mL茄形瓶中加入3.50mmol实施例3产物、5.25mmol碳酸钾和10mL丙酮。搅拌下滴加4.20mmol胺类化合物，加热回流反应6-8h。减压蒸除丙酮，加入10mL饱和盐水，转移至分液漏斗中，用二氯甲烷萃取，合并有机相，无水硫酸钠干燥。浓缩后得化合物1-10。
按此合成方法得到：
化合物1：白色固体。熔点82.5-83.5℃。MS(EI)[M+H]+m/z:293.2587.1H NMR(300MHz,CDCl3)δ(ppm):5.68(1H,br s),4.96,4.94(2H,s,s),3.93(1H,t,J=6.7Hz),3.11–2.85(4H,m),2.85–2.71(2H,m,),2.34–2.15(3H,m),2.06–1.82(2H,m),1.65–1.41(6H,m),1.06(6H,d,J=6.4Hz),0.86(3H,t,J=7.4Hz).
化合物2：白色固体。熔点67-69℃。MS(EI)[M+H]+m/z:371.2692.1H NMR(300MHz,CDCl3)δ(ppm):6.98-6.78(4H,m),5.69(1H,br s),5.01,4.94(2H,s,s),3.94(1H,t,J=6.6Hz),3.78(3H,s),3.26-2.86(6H,m),2.78-2.37(4H,m),2.33–1.88(6H,m),1.62–1.52(3H,m),0.90(3H,t,J=7.4Hz).
化合物3：无色油状物。MS(EI)[M+H]+m/z:371.2694.1H NMR(600MHz,CDCl3)δ(ppm):7.01–6.84(4H,m),5.68(1H,br s),5.00,4.91(2H,s,s),3.92(1H,t,J=6.6Hz),3.86(3H,s),3.21–2.92(6H,m),2.73-2.46(4H,m),2.31–2.18(3H,m),2.04–1.86(3H,m),1.59–1.48(3H,m),0.89(3H,t,J=7.4Hz).
化合物4：白色固体。熔点53-55℃。MS(EI)[M+H]+m/z:307.2745.1H NMR(300MHz,CDCl3)δ(ppm):5.67(1H,br s),,4.95,4.88(2H,s,s),3.91(1H,t,J=6.6Hz),2.92(2H,s),2.78–2.36(9H,m),2.32-1.79(6H,m),1.60–1.45(3H,m),1.06(6H,d,J=6.4Hz),0.88(3H,t,J=7.4Hz).
化合物5：无色油状物。MS(EI)[M+H]+m/z:355.2742.1H NMR(300MHz,CDCl3)δ(ppm):7.38–7.20(5H,m),5.66(1H,br s),4.94,4.87(2H,,s,s),3.91(1H,t,J=6.6Hz),3.51(2H,s),2.92(2H,s),),2.55-2.16(9H,m),2.06–1.41(8H,m),0.89(3H,t,J=7.4Hz).
化合物6:白色固体。熔点74-76℃。MS(EI)[M+H]+m/z:265.2274.1H NMR(300MHz,CDCl3)δ(ppm):5.69(1H,br s),4.95,4.88(2H,s,s),4.30–4.11(1H,m),3.02–2.79(5H,m),2.75,2.72(2H,s,s),2.30-2.17(9H,m),1.56-1.43(1H,m),1.27(3H,d,J=6.5Hz),1.04(3H,d,J=6.3Hz).
化合物7:白色固体。熔点90-92℃。MS(EI)[M+H]+m/z:279.2432.1H NMR(300MHz,CDCl3)δ(ppm):5.69(1H,br s),4.96,4.89(2H,s,s),4.40–4.07(1H,m),3.04–2.83(4H,m),2.77,2.74(2H,s,s),2.23(2H,m),2.18–1.82(3H,m),1.68–1.40(4H,m),1.29(3H,d,J=6.5Hz),1.05(6H,d,J=6.4Hz).
化合物8:白色固体。熔点46-48℃。MS(EI)[M+H]+m/z:357.2537.1H NMR(300MHz,CDCl3)δ(ppm):6.97-6.74(4H,m),5.70(1H,br s),5.01,4.92(2H,s,s),4.35–4.09(1H,m),3.78(3H,s),3.20-2.90(6H,m),2.71-2.42(4H,m),2.40-1.80(5H,m),1.60–1.37(2H,m),1.28(3H,d,J=6.4Hz).
化合物9:淡黄色油状物。MS(EI)[M+H]+m/z:357.2537.1H NMR(300MHz,CDCl3)δ(ppm):7.09–6.80(4H,m),5.70(1H,br s),5.00,4.91(2H,s,s),4.30–4.11(1H,m),3.86(3H,s),3.21-2.91(6H,m),2.73-2.42(4H,m),2.41-1.80(5H,m),1.58–1.38(2H,m),1.27(3H,d,J=6.4Hz).
化合物10:淡黄色油状物。MS(EI)[M+H]+m/z:293.2587.1H NMR(300MHz,CDCl3)δ(ppm):5.69(1H,br s),4.96,4.87(2H,s,s),4.30-4.10(1H,m),3.00–2.84(2H,m),2.73–2.35(9H,m),2.30–1.82(5H,m),1.81–1.42(2H,m),1.27(3H,d,J=6.5Hz),1.07(6H,d,J=6.5Hz).
实施例5
用MTT法测定了目标化合物对人肝癌细胞HepG2，人结肠癌细胞HCT116，人肺癌细胞A549，人黑色素瘤细胞A375-S2和人纤维肉瘤细胞HT-1080五类肿瘤细胞的增殖抑制作用。
1）贴壁细胞选用对数生长期的贴壁肿瘤细胞，用胰酶消化后，用含10％小牛血清的RPMI l640培养基配成5×104/ml的细胞悬液，接种在96孔培养板中，每孔100μl，37℃，5％CO2培养24h。实验组更换新的含不同浓度被测样品（10～100μmol·L-1）的培养液，对照组则更换含等体积溶剂的培养液，每组设3个平行孔，37℃，5％CO2培养48h。弃去上清液，用PBS小心洗2次，每孔加入100μl新鲜配制的含0.5mg/ml MTT的培养基，37℃继续培养4h。小心弃去上清，并加入150μl DMSO，用微型振荡器混匀10min后，用酶标仪在492nm处测定光密度值(OD)。
2）悬浮细胞选用对数生长期的细胞，用含10％小牛血清的RPMI l640培养基配成1×104/ml的细胞悬液，接种在96孔培养板中，每孔50μl，37℃，5％CO2培养24h。实验组加入含不同浓度被测样品（10～100μmol·L-1）的培养液50μl，对照组则加入含等体积溶剂的培养液，每组设3个平行孔，37℃，5％CO2培养48h，每孔加入10μl新鲜配制的含5mg/ml MTT的培养基，37℃继续培养4h。用三联液（SDS10g，10M HCl0.1mL，异丁醇5mL，用蒸馏水稀释至100mL）100μl溶解结晶，37℃孵育12h。用酶标仪在492nm处测定光密度值(OD)。
按以下公式计算药物对肿瘤细胞体外增殖的抑制率（Inhibition Rate，IR%）：
IR%=（1-ODsample/ODcontrol）×100%
用ICP1.0.0软件计算药物的半数抑制浓度（IC50）。
结果见下表，与紫苏醇比较，所有目标化合物抑制五种肿瘤细胞株的IC50值均有所降低，因此在紫苏醇羟基α-碳原子上引入烷基，并在环外烯丙位引入胺类基团，可以提高紫苏醇的体外抗肿瘤活性。
表1式Ⅰ化合物和紫苏醇对肿瘤细胞的IC50值
Claims (4)
1.一种紫苏醇类似物及其盐，选自：
2.如权利要求1所述的紫苏醇类似物及其盐，其特征在于，所述的盐指常规的酸加成盐，所述的酸为有机酸或无机酸，选自盐酸，氢溴酸，氢碘酸，硫酸，磷酸，硝酸，乙酸，酒石酸，水杨酸，甲磺酸，丁二酸，柠檬酸，苹果酸，乳酸，富马酸或马来酸。
3.一种药物组合物，其特征在于，包含权利要求1所述的紫苏醇类似物及其盐和药学上可被接受的赋形剂。
4.权利要求1所述紫苏醇类似物及其盐或权利要求3所述的组合物在制备抗肿瘤药物中的应用，所述的肿瘤为肝癌、纤维肉瘤、结肠癌、黑色素瘤或肺癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410119248.XA CN104945333B (zh) | 2014-03-27 | 2014-03-27 | 紫苏醇类似物及其制备和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410119248.XA CN104945333B (zh) | 2014-03-27 | 2014-03-27 | 紫苏醇类似物及其制备和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104945333A CN104945333A (zh) | 2015-09-30 |
| CN104945333B true CN104945333B (zh) | 2018-02-02 |
Family
ID=54160464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410119248.XA Expired - Fee Related CN104945333B (zh) | 2014-03-27 | 2014-03-27 | 紫苏醇类似物及其制备和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104945333B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105837422A (zh) * | 2016-04-20 | 2016-08-10 | 宋晓梅 | 一种盐酸丁丙诺啡的药物组合物及其在生物医药中的应用 |
| CN108586330A (zh) * | 2018-04-18 | 2018-09-28 | 日照市普达医药科技有限公司 | 一种治疗肿瘤药物的制备方法及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850779A (zh) * | 2006-05-10 | 2006-10-25 | 沈阳药科大学 | β－榄香烯含氮衍生物及其制备方法和用途 |
| CN101070300A (zh) * | 2006-05-10 | 2007-11-14 | 沈阳药科大学 | 柠檬烯类似物及其制备方法和用途 |
| CN101429175A (zh) * | 2008-12-12 | 2009-05-13 | 天津工业大学 | 一种具有抗肿瘤活性的紫苏醇衍生物及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2856403A1 (en) * | 2011-11-21 | 2013-08-15 | Neonc Technologies Inc. | Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof |
-
2014
- 2014-03-27 CN CN201410119248.XA patent/CN104945333B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850779A (zh) * | 2006-05-10 | 2006-10-25 | 沈阳药科大学 | β－榄香烯含氮衍生物及其制备方法和用途 |
| CN101070300A (zh) * | 2006-05-10 | 2007-11-14 | 沈阳药科大学 | 柠檬烯类似物及其制备方法和用途 |
| CN101429175A (zh) * | 2008-12-12 | 2009-05-13 | 天津工业大学 | 一种具有抗肿瘤活性的紫苏醇衍生物及其用途 |
Non-Patent Citations (3)
| Title |
|---|
| STRUCTURE-ACTIVITY RELATIONSHIPS AMONG MONOTERPENE INHIBITORS OF PROTEIN ISOPRENYLATION AND CELL PROLIFERATION;PAMELA L. CROWELL;《Biochemical Pharmacology》;19941231;第47卷(第8期);第1405-1415页，第1407页化合物M2、M3 * |
| The synthesis of L-carvone and limonene derivatives with increased antiproliferative effect and activation of ERK pathway in prostate cancer cells;Jiaojiao Chen et al;《Bioorg. Med. Chem.》;20060627;第14卷;第6539–6547页，第6540页图2，第6541-6542页表1 * |
| 柠檬烯类似物的设计、合成及抗癌活性研究;陈娇娇;《中国博士学位论文全文数据库，医药卫生科技辑》;20111115;E079-7，正文第14页，第17页最后1段，第18页图1.20，第21-22页，第33-37页表3.1-表3.3，第30页图2.3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104945333A (zh) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106029653A (zh) | 二氨基嘧啶苯砜衍生物及其用途 | |
| CN104974182B (zh) | 酞菁硅配合物、其制备方法及其在医药上的应用 | |
| CN104693257B (zh) | 苯磺酰基呋咱修饰的吉西他滨衍生物及其制备方法和用途 | |
| CN106795114A (zh) | 新颖的亚氨基腈衍生物 | |
| CN106572991A (zh) | 用于克服铂耐受性的德克萨卟啉‑pt(iv)缀合物及组合物 | |
| CN104945333B (zh) | 紫苏醇类似物及其制备和应用 | |
| CN107663224A (zh) | 丹参酮iia衍生物及其制备方法 | |
| CN106565763B (zh) | pH敏感的轴向取代硅酞菁配合物及其制备方法和在医药上的应用 | |
| CN106749478B (zh) | pH敏感的1,4‑二取代酞菁锌配合物及其制备方法和在医药上的应用 | |
| CN109942630B (zh) | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 | |
| CN105130897B (zh) | 一类含氮硫取代基的萘酰亚胺化合物，其制备方法及应用 | |
| CN112608302B (zh) | 低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用 | |
| CN104945334B (zh) | 紫苏醇衍生物及其制备和应用 | |
| CN107108584A (zh) | 抗病毒剂及其应用 | |
| CN104945335B (zh) | 紫苏胺类化合物及其制备和应用 | |
| CN109096219A (zh) | 一种新型抗pd-l1化合物、其应用及含其的组合物 | |
| CN104530127B (zh) | 一种淫羊藿苷衍生物及其使用方法和用途 | |
| CN106913564A (zh) | 聚醚类化合物用途 | |
| CN104098457B (zh) | 四氢姜黄素类似物及其制备和应用 | |
| CN102746212B (zh) | β-榄香烯吲哚衍生物及其制备和应用 | |
| CN109824753A (zh) | 具有ido/tdo双选择性抑制活性的丹参酮iia衍生物 | |
| CN107739381A (zh) | 莪术醇衍生物及其在制备抗肿瘤药物中的应用 | |
| CN105367575B (zh) | 一种叶酸类化合物、其制备方法及医药用途 | |
| CN110981865B (zh) | 一种用于治疗脑胶质瘤的药物及其制备方法 | |
| CN107513089B (zh) | 一种新型胞苷衍生物二聚体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180202 |